The Distillery of the Future: Why the DOJ’s Rescheduling Order Signals a New Legal Era
Ironleaf Law Firm
On April 22–23, 2026, the Department of Justice issued an order placing FDA‑approved marijuana products and marijuana products subject to a qualifying state medical license into Schedule III, and the DOJ/DEA set an expedited administrative hearing beginning June 29, 2026, to consider broader rescheduling. Adult‑use cannabis remains Schedule I.
What changed for taxes and operations
Section 280E applies only to trafficking in Schedule I and II substances. By moving qualifying state‑licensed medical cannabis into Schedule III, the Order removes the statutory bar that previously prevented ordinary business deductions for qualifying medical activity—but only for transactions governed by a state medical license. Expect Treasury/IRS guidance and litigation over retroactivity and allocation.
How this works in Montana — practical rules
- Trigger is the license under which the sale occurs, not the strain or SKU. A product sold to a registered medical patient under Montana’s medical endorsement is treated as Schedule III; the same physical product sold as adult‑use is Schedule I.
- Dual‑license operators must segregate revenue, inventory, and costs; allocation methods will be scrutinized by the IRS. Aggressive positions treating all revenue as medical are high risk.
| Operator Type | Federal Status | 280E exposure | Immediate Action |
|---|---|---|---|
| Medical-only | Schedule III for qualifying sales | Low for qualifying sales | Prepare deductions; consult counsel before amended returns. |
| Dual-license | Medical sales Schedule III; adult-use Schedule I | Mixed; must allocate | Segregate POS/Metric tags; document cost allocation |
| Adult-use only | Schedule I | High (no relief) | Consider medical channel or tax planning |
Compliance and Strategic Priorities for Montana Extraction Labs
1. Accounting and POS segregation. Tag every medical sale in Metrc and your POS; create separate revenue codes and cost centers.
2. Documentation. Preserve transaction‑level evidence showing the license under which each transfer occurred.
3. Good Manufacturing Practices (GMP) and DEA readiness. If you plan to seek DEA registration or participate in interstate research, begin GMP‑style SOPs and facility documentation now—DEA registration pathways were contemplated in the Order.
Research, markets, and limits
Schedule III status for state‑licensed medical products opens research access to state‑licensed product and reduces administrative barriers for clinical trials, but this is a staged, partial normalization—adult‑use and unlicensed product remain Schedule I, and novel synthetic cannabinoids remain excluded. Expect a multi‑year regulatory and litigation arc.
Ironleaf Action Plan
If you operate in Montana, start now: (1) segregate medical vs adult‑use sales and costs; (2) consult tax counsel before filing amended returns or protective claims; (3) begin GMP documentation if you intend to pursue DEA registration or research partnerships. We can help map accounting structures, draft allocation policies, and prepare DEA/GMP readiness packages ahead of the June hearing.
